

ABSTRACT OF THE DISCLOSURE

This invention discloses methods, kits, and instructions to treat neovascu-  
lature diseases of the eye through the administration of a targeted photosensitizing agent  
and subsequent exposure to light of specific wavelength sufficient to photoactivate  
photosensitizing agent. The photosensitizing agent is bound to a composition that  
mediates site specific delivery to a neovascu-  
lature target tissue of a therapeutically  
effective amount of a photosensitizing agent that is activated by a relatively low  
fluence rate of light over a prolonged period of time. Diseases treatable under this  
invention, include: diabetic retinopathy; macular degeneration; and malignant uveal  
melanomas.